Gefitinib in patients with progressive high-grade gliomas

A multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)

E. Franceschi, G. Cavallo, S. Lonardi, E. Magrini, A. Tosoni, D. Grosso, L. Scopece, V. Blatt, B. Urbini, A. Pession, G. Tallini, L. Crinò, A. A. Brandes

Research output: Contribution to journalArticle

141 Citations (Scopus)

Abstract

To investigate the role of gefitinib in patients with high-grade gliomas (HGGs), a phase II trial (1839IL/0116) was conducted in patients with disease recurrence following surgery plus radiotherapy and first-line chemotherapy. Adult patients with histologically confirmed recurrent HGGs following surgery, radiotherapy and first-line chemotherapy, were considered eligible. Patients were treated with gefitinib (250 mgday-1) continuously until disease progression. The primary end point was progression-free survival at 6 months progression-free survival at 6 months (PFS-6). Tissue biomarkers (epidermal growth factor receptor (EGFR) gene status and expression, phosphorylated Akt (p-Akt) expression) were assessed. Twenty-eight patients (median age, 55 years; median ECOG performance status, 1) were enrolled; all were evaluable for drug activity and safety. Sixteen patients had glioblastoma, three patients had anaplastic oligodendrogliomas and nine patients had anaplastic astrocytoma. Five patients (17.9%, 95% CI 6.1-36.9%) showed disease stabilisation. The overall median time to progression was 8.4 (range 2-104+) weeks and PFS-6 was 14.3% (95% CI 4.0-32.7%). The median overall survival was 24.6 weeks (range 4-104+). No grade 3-4 gefitinib-related toxicity was found. Gefitinib showed limited activity in patients affected by HGGs. Epidermal growth factor receptor expression or gene status, and p-Akt expression do not seem to predict activity of this drug.

Original languageEnglish
Pages (from-to)1047-1051
Number of pages5
JournalBritish Journal of Cancer
Volume96
Issue number7
DOIs
Publication statusPublished - Apr 10 2007

Fingerprint

Glioma
Disease-Free Survival
Radiotherapy
gefitinib
erbB-1 Genes
Gene Expression
Oligodendroglioma
Drug Therapy
Astrocytoma
Glioblastoma
Epidermal Growth Factor Receptor
Pharmaceutical Preparations
Disease Progression
Biomarkers
Safety
Recurrence
Survival

Keywords

  • Akt
  • EGFR
  • Gefitinib
  • High-grade gliomas

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gefitinib in patients with progressive high-grade gliomas : A multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). / Franceschi, E.; Cavallo, G.; Lonardi, S.; Magrini, E.; Tosoni, A.; Grosso, D.; Scopece, L.; Blatt, V.; Urbini, B.; Pession, A.; Tallini, G.; Crinò, L.; Brandes, A. A.

In: British Journal of Cancer, Vol. 96, No. 7, 10.04.2007, p. 1047-1051.

Research output: Contribution to journalArticle

Franceschi, E, Cavallo, G, Lonardi, S, Magrini, E, Tosoni, A, Grosso, D, Scopece, L, Blatt, V, Urbini, B, Pession, A, Tallini, G, Crinò, L & Brandes, AA 2007, 'Gefitinib in patients with progressive high-grade gliomas: A multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)', British Journal of Cancer, vol. 96, no. 7, pp. 1047-1051. https://doi.org/10.1038/sj.bjc.6603669
Franceschi, E. ; Cavallo, G. ; Lonardi, S. ; Magrini, E. ; Tosoni, A. ; Grosso, D. ; Scopece, L. ; Blatt, V. ; Urbini, B. ; Pession, A. ; Tallini, G. ; Crinò, L. ; Brandes, A. A. / Gefitinib in patients with progressive high-grade gliomas : A multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). In: British Journal of Cancer. 2007 ; Vol. 96, No. 7. pp. 1047-1051.
@article{01355a5df28e44a5b221c674cbdba37a,
title = "Gefitinib in patients with progressive high-grade gliomas: A multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)",
abstract = "To investigate the role of gefitinib in patients with high-grade gliomas (HGGs), a phase II trial (1839IL/0116) was conducted in patients with disease recurrence following surgery plus radiotherapy and first-line chemotherapy. Adult patients with histologically confirmed recurrent HGGs following surgery, radiotherapy and first-line chemotherapy, were considered eligible. Patients were treated with gefitinib (250 mgday-1) continuously until disease progression. The primary end point was progression-free survival at 6 months progression-free survival at 6 months (PFS-6). Tissue biomarkers (epidermal growth factor receptor (EGFR) gene status and expression, phosphorylated Akt (p-Akt) expression) were assessed. Twenty-eight patients (median age, 55 years; median ECOG performance status, 1) were enrolled; all were evaluable for drug activity and safety. Sixteen patients had glioblastoma, three patients had anaplastic oligodendrogliomas and nine patients had anaplastic astrocytoma. Five patients (17.9{\%}, 95{\%} CI 6.1-36.9{\%}) showed disease stabilisation. The overall median time to progression was 8.4 (range 2-104+) weeks and PFS-6 was 14.3{\%} (95{\%} CI 4.0-32.7{\%}). The median overall survival was 24.6 weeks (range 4-104+). No grade 3-4 gefitinib-related toxicity was found. Gefitinib showed limited activity in patients affected by HGGs. Epidermal growth factor receptor expression or gene status, and p-Akt expression do not seem to predict activity of this drug.",
keywords = "Akt, EGFR, Gefitinib, High-grade gliomas",
author = "E. Franceschi and G. Cavallo and S. Lonardi and E. Magrini and A. Tosoni and D. Grosso and L. Scopece and V. Blatt and B. Urbini and A. Pession and G. Tallini and L. Crin{\`o} and Brandes, {A. A.}",
year = "2007",
month = "4",
day = "10",
doi = "10.1038/sj.bjc.6603669",
language = "English",
volume = "96",
pages = "1047--1051",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Gefitinib in patients with progressive high-grade gliomas

T2 - A multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)

AU - Franceschi, E.

AU - Cavallo, G.

AU - Lonardi, S.

AU - Magrini, E.

AU - Tosoni, A.

AU - Grosso, D.

AU - Scopece, L.

AU - Blatt, V.

AU - Urbini, B.

AU - Pession, A.

AU - Tallini, G.

AU - Crinò, L.

AU - Brandes, A. A.

PY - 2007/4/10

Y1 - 2007/4/10

N2 - To investigate the role of gefitinib in patients with high-grade gliomas (HGGs), a phase II trial (1839IL/0116) was conducted in patients with disease recurrence following surgery plus radiotherapy and first-line chemotherapy. Adult patients with histologically confirmed recurrent HGGs following surgery, radiotherapy and first-line chemotherapy, were considered eligible. Patients were treated with gefitinib (250 mgday-1) continuously until disease progression. The primary end point was progression-free survival at 6 months progression-free survival at 6 months (PFS-6). Tissue biomarkers (epidermal growth factor receptor (EGFR) gene status and expression, phosphorylated Akt (p-Akt) expression) were assessed. Twenty-eight patients (median age, 55 years; median ECOG performance status, 1) were enrolled; all were evaluable for drug activity and safety. Sixteen patients had glioblastoma, three patients had anaplastic oligodendrogliomas and nine patients had anaplastic astrocytoma. Five patients (17.9%, 95% CI 6.1-36.9%) showed disease stabilisation. The overall median time to progression was 8.4 (range 2-104+) weeks and PFS-6 was 14.3% (95% CI 4.0-32.7%). The median overall survival was 24.6 weeks (range 4-104+). No grade 3-4 gefitinib-related toxicity was found. Gefitinib showed limited activity in patients affected by HGGs. Epidermal growth factor receptor expression or gene status, and p-Akt expression do not seem to predict activity of this drug.

AB - To investigate the role of gefitinib in patients with high-grade gliomas (HGGs), a phase II trial (1839IL/0116) was conducted in patients with disease recurrence following surgery plus radiotherapy and first-line chemotherapy. Adult patients with histologically confirmed recurrent HGGs following surgery, radiotherapy and first-line chemotherapy, were considered eligible. Patients were treated with gefitinib (250 mgday-1) continuously until disease progression. The primary end point was progression-free survival at 6 months progression-free survival at 6 months (PFS-6). Tissue biomarkers (epidermal growth factor receptor (EGFR) gene status and expression, phosphorylated Akt (p-Akt) expression) were assessed. Twenty-eight patients (median age, 55 years; median ECOG performance status, 1) were enrolled; all were evaluable for drug activity and safety. Sixteen patients had glioblastoma, three patients had anaplastic oligodendrogliomas and nine patients had anaplastic astrocytoma. Five patients (17.9%, 95% CI 6.1-36.9%) showed disease stabilisation. The overall median time to progression was 8.4 (range 2-104+) weeks and PFS-6 was 14.3% (95% CI 4.0-32.7%). The median overall survival was 24.6 weeks (range 4-104+). No grade 3-4 gefitinib-related toxicity was found. Gefitinib showed limited activity in patients affected by HGGs. Epidermal growth factor receptor expression or gene status, and p-Akt expression do not seem to predict activity of this drug.

KW - Akt

KW - EGFR

KW - Gefitinib

KW - High-grade gliomas

UR - http://www.scopus.com/inward/record.url?scp=34247218483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247218483&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6603669

DO - 10.1038/sj.bjc.6603669

M3 - Article

VL - 96

SP - 1047

EP - 1051

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 7

ER -